The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.
On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.
The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.
After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.
The Clorox Company director reported routine equity compensation activity in the form of deferred stock units. The filing shows several acquisitions of deferred stock units tied to Clorox common stock during 2025, including transactions dated 02/14/2025, 05/09/2025, 08/29/2025, 11/06/2025, and 12/31/2025. These awards were recorded at an exercise price of $0.0000 per unit.
The director’s beneficial holdings in these derivative securities increased to 15,677.4328 deferred stock units held directly. The explanation notes that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, while an additional annual award was granted under the 2005 Stock Incentive Plan. Each deferred stock unit represents a 1-for-1 right to receive Clorox stock, to be settled in shares upon the director’s retirement or other termination of service from the board.
The Clorox Company director reports routine deferred stock awards. A board member of Clorox (ticker CLX) reported several grants of deferred stock units that each convert 1-for-1 into Clorox common stock. On 11/06/2025, the director acquired 219.3396 deferred stock units, bringing the beneficial holding to 19,018.8638 units. On 12/31/2025, additional awards of 1,219.1572 and 145.2617 deferred stock units increased the total to 20,383.2827 units held directly.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent the annual deferred stock unit award under the 2005 Stock Incentive Plan, and some reflect stock units received instead of a portion of quarterly director fees. All deferred stock units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Co. director deferred stock unit grants and reinvestments
A director of Clorox Co. reported multiple acquisitions of deferred stock units tied to Clorox common stock during 2025. On several dates, including 02/14/2025, 05/09/2025, 08/29/2025, and 11/06/2025, small fractional amounts of deferred stock units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, each at an exercise price of $0.0000 and on a 1-for-1 basis into Clorox stock.
On 12/31/2025, the director received an additional 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, also with a conversion price of $0.0000. Following these transactions, the director beneficially owned a total of 4,471.9997 deferred stock units, which will be settled 100% in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.
On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.
The Clorox Company reported a routine equity grant to a director. On 12/31/2025, the director received an annual award of 1-for-1 Deferred Stock Units under the company’s 2005 Stock Incentive Plan. The transaction, reported on a Form 4 for one reporting person, shows 1,637.8577 Deferred Stock Units credited at a price of $0.0000 per unit.
The Deferred Stock Units are tied to Clorox common stock and will be settled 100% in Clorox shares in connection with the director’s retirement or other termination of board service. The filing characterizes this as an annual award, reflecting ongoing non-cash compensation for board service rather than an open-market purchase or sale.
The Clorox Company director reports a routine stock-based compensation grant. A board member received an annual award of 825.0862 Deferred Stock Units on 12/31/2025 under the company’s 2005 Stock Incentive Plan. Each unit is described as a 1-for-1 right tied to a share of Clorox common stock, with a stated price of $0.0000 per unit, indicating this is a compensation award rather than an open‑market purchase. The filing states these Deferred Stock Units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board, so the director’s economic interest in the company increases but actual shares will be issued in the future.
Clorox Co (CLX) reported an insider equity transaction by its EVP and Chief Operating Officer. On 12/12/2025, the executive had 255 shares of Clorox common stock withheld at $102.83 per share in a transaction coded F, which the company explains was to satisfy employment tax obligations tied to previously granted restricted stock units for a retirement-eligible employee. Following this withholding, the executive directly beneficially owns 69,058 shares of Clorox common stock.